INCY
Price
$84.61
Change
+$0.91 (+1.09%)
Updated
Aug 29 closing price
Capitalization
16.52B
64 days until earnings call
REGN
Price
$580.70
Change
+$1.09 (+0.19%)
Updated
Aug 29 closing price
Capitalization
61.55B
59 days until earnings call
Interact to see
Advertisement

INCY vs REGN

Header iconINCY vs REGN Comparison
Open Charts INCY vs REGNBanner chart's image
Incyte
Price$84.61
Change+$0.91 (+1.09%)
Volume$1.34M
Capitalization16.52B
Regeneron Pharmaceuticals
Price$580.70
Change+$1.09 (+0.19%)
Volume$574.38K
Capitalization61.55B
INCY vs REGN Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. REGN commentary
Sep 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and REGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 01, 2025
Stock price -- (INCY: $84.61 vs. REGN: $580.70)
Brand notoriety: INCY and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 77% vs. REGN: 63%
Market capitalization -- INCY: $16.52B vs. REGN: $61.55B
INCY [@Biotechnology] is valued at $16.52B. REGN’s [@Biotechnology] market capitalization is $61.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 5 bearish.
  • REGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а -0.51% price change this week, while REGN (@Biotechnology) price change was -1.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

INCY is expected to report earnings on Nov 04, 2025.

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($61.5B) has a higher market cap than INCY($16.5B). INCY has higher P/E ratio than REGN: INCY (20.00) vs REGN (14.63). INCY YTD gains are higher at: 22.499 vs. REGN (-18.129). REGN has higher annual earnings (EBITDA): 5.42B vs. INCY (1.36B). INCY has less debt than REGN: INCY (42.4M) vs REGN (2.71B). REGN has higher revenues than INCY: REGN (14.2B) vs INCY (4.59B).
INCYREGNINCY / REGN
Capitalization16.5B61.5B27%
EBITDA1.36B5.42B25%
Gain YTD22.499-18.129-124%
P/E Ratio20.0014.63137%
Revenue4.59B14.2B32%
Total Cash2.42BN/A-
Total Debt42.4M2.71B2%
FUNDAMENTALS RATINGS
INCY vs REGN: Fundamental Ratings
INCY
REGN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3853
PRICE GROWTH RATING
1..100
1060
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for INCY (59). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.

REGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCY (100). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

INCY's SMR Rating (38) in the Biotechnology industry is in the same range as REGN (53). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

INCY's Price Growth Rating (10) in the Biotechnology industry is somewhat better than the same rating for REGN (60). This means that INCY’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as INCY (100). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYREGN
RSI
ODDS (%)
Bearish Trend 4 days ago
59%
Bearish Trend 4 days ago
33%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
56%
Bearish Trend 4 days ago
53%
Momentum
ODDS (%)
Bearish Trend 4 days ago
60%
Bullish Trend 4 days ago
67%
MACD
ODDS (%)
Bearish Trend 4 days ago
66%
Bullish Trend 4 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 4 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
61%
Bullish Trend 4 days ago
63%
Advances
ODDS (%)
Bullish Trend 12 days ago
61%
Bullish Trend 12 days ago
61%
Declines
ODDS (%)
Bearish Trend 7 days ago
59%
Bearish Trend 5 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
66%
Bearish Trend 4 days ago
51%
Aroon
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PBNV28.59N/A
N/A
PGIM S&P 500 Buffer 20 ETF - Nov
UOCT37.89-0.08
-0.21%
Innovator U.S. Equity Ultra Buf ETF™ Oct
QDEC30.11-0.23
-0.76%
FT Vest Nasdaq-100 Buffer ETF – Dec
ROKT71.60-0.78
-1.07%
SPDR® Kensho Final Frontiers ETF
SPXL193.01-3.66
-1.86%
Direxion Daily S&P500® Bull 3X ETF

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with TECH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+1.09%
TECH - INCY
42%
Loosely correlated
+0.55%
AXON - INCY
39%
Loosely correlated
-4.43%
REGN - INCY
38%
Loosely correlated
+0.19%
LGND - INCY
37%
Loosely correlated
+1.09%
SYRE - INCY
37%
Loosely correlated
-1.38%
More